Document Detail

The effect of controlled aprotinin administration through cardiotomy suction during cardiopulmonary bypass.
MedLine Citation:
PMID:  12395967     Owner:  NLM     Status:  MEDLINE    
Cardiotomy suction enhances inflammation and fibrinolysis during cardiopulmonary bypass (CPB). Aprotinin has been shown to reduce the generalized inflammatory insults associated with CPB. The purpose of this study was to evaluate the effect of Aprotinin administration through cardiotomy suction on the inflammatory and fibrinolytic responses during CPB. A pig model of CPB was utilized including 8 animals divided into control and treatment groups. In the treatment group, Aprotinin was infused into the cardiotomy suction (3000 KIU/min), while the same volume of saline was infused in the control group. D-dimer, platelet count, and IL-8 level were analyzed from systemic and cardiotomy suction. It was found that Aprotinin significantly suppressed the increase in D-dimer levels in the systemic (476.3 +/- 341.2 vs. 1218.8 +/- 281.3 ng/ml, p < 0.05) and the cardiotomy suction (565.0 +/- 192.5 vs. 1875.0 +/- 125.0 ng/ml, p < 0.05). Platelet count fell in both groups during CPB, although the reduction was greater in the control (13.1 +/- 5.1 vs. 37.9 +/- 13.8%, p < 0.05). In addition, IL-8 level in the suction solution was significantly lower in the Aprotinin group (56.5 +/- 18.0 vs. 136.3 +/- 14.8 pg/ml, p < 0.05). In conclusion, this study suggested that Aprotinin treatment of the cardiotomy solution might be an effective way of reducing fibrinolysis, platelet reduction, and inflammation associated with CPB.
Jun-Li Liu; Alfred H Stammers; Hong Zheng; Nancy J Mills; Jeffery D Nichols; Scott A Kmiecik; Ryan J Kohtz; Craig M Petterson
Related Documents :
12297167 - Reduction of the inflammatory response following coronary bypass grafting with total mi...
16816947 - The efficacy of autologous platelet gel in pain control and blood loss in total knee ar...
11565897 - Heparin-coated cardiopulmonary bypass circuits: current status.
18017 - Function of human platelets during extracorporeal circulation.
18983227 - The chimeric monoclonal antibody abciximab: a systematic review of its safety in contem...
17508337 - Energizing an invertebrate embryo: bafilomycin-dependent respiration and the metabolic ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of extra-corporeal technology     Volume:  34     ISSN:  0022-1058     ISO Abbreviation:  J Extra Corpor Technol     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-10-24     Completed Date:  2002-11-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0267637     Medline TA:  J Extra Corpor Technol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  203-8     Citation Subset:  T    
Division of Clinical Perfusion Education, University of Nebraska Medical Center, School of Allied Health Professionals, Omaha 68198-5155, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aprotinin / administration & dosage*,  therapeutic use
Cardiopulmonary Bypass*
Fibrin Fibrinogen Degradation Products / analysis
Interleukin-8 / analysis
Platelet Count
Suction / adverse effects*
United States
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/Interleukin-8; 0/fibrin fragment D; 9087-70-1/Aprotinin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effects of ultrafiltration on e-aminocaproic acid: an in vitro analysis.
Next Document:  CAPS--coronary-assisted perfusion system.